These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 19280191)

  • 1. A phase I dose escalation study of the pharmacokinetics and tolerability of ZK 304709, an oral multi-targeted growth inhibitor (MTGI), in patients with advanced solid tumours.
    Scott EN; Thomas AL; Molife LR; Ahmed S; Blagden S; Fong PC; Kowal K; McCoy C; Wiesinger H; Steward W; De Bono J
    Cancer Chemother Pharmacol; 2009 Jul; 64(2):425-9. PubMed ID: 19280191
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Open-label, non-randomised, inter-individual dose escalation of ZK 304709 with the evaluation of safety, tolerability, pharmacokinetics, oral bioavailability and orientating efficacy after daily administration in patients with advanced cancer (7 d treatment and 14 d recovery).
    Graham JS; Plummer R; McCoy C; Kowal K; Wiesinger H; Detjen K; Calvert H; Wiedenmann B; Cassidy J
    Eur J Cancer; 2008 Oct; 44(15):2162-8. PubMed ID: 18653327
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I dose escalation study of telatinib, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor 2 and 3, platelet-derived growth factor receptor beta, and c-Kit, in patients with advanced or metastatic solid tumors.
    Eskens FA; Steeghs N; Verweij J; Bloem JL; Christensen O; van Doorn L; Ouwerkerk J; de Jonge MJ; Nortier JW; Kraetzschmar J; Rajagopalan P; Gelderblom H
    J Clin Oncol; 2009 Sep; 27(25):4169-76. PubMed ID: 19636022
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of PTK787/ZK 222584 administered twice daily in patients with advanced cancer.
    Thomas AL; Morgan B; Horsfield MA; Higginson A; Kay A; Lee L; Masson E; Puccio-Pick M; Laurent D; Steward WP
    J Clin Oncol; 2005 Jun; 23(18):4162-71. PubMed ID: 15867205
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I clinical and pharmacokinetic study of PTK/ZK, a multiple VEGF receptor inhibitor, in patients with liver metastases from solid tumours.
    Mross K; Drevs J; Müller M; Medinger M; Marmé D; Hennig J; Morgan B; Lebwohl D; Masson E; Ho YY; Günther C; Laurent D; Unger C
    Eur J Cancer; 2005 Jun; 41(9):1291-9. PubMed ID: 15939265
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase 1 study of the investigational, oral angiogenesis inhibitor motesanib in Japanese patients with advanced solid tumors.
    Fujisaka Y; Yamada Y; Yamamoto N; Shimizu T; Fujiwara Y; Yamada K; Tamura T; Watanabe H; Sun YN; Bass MB; Seki M
    Cancer Chemother Pharmacol; 2010 Oct; 66(5):935-43. PubMed ID: 20107802
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies.
    Mita MM; Mita AC; Chu QS; Rowinsky EK; Fetterly GJ; Goldston M; Patnaik A; Mathews L; Ricart AD; Mays T; Knowles H; Rivera VM; Kreisberg J; Bedrosian CL; Tolcher AW
    J Clin Oncol; 2008 Jan; 26(3):361-7. PubMed ID: 18202410
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results.
    Rugo HS; Herbst RS; Liu G; Park JW; Kies MS; Steinfeldt HM; Pithavala YK; Reich SD; Freddo JL; Wilding G
    J Clin Oncol; 2005 Aug; 23(24):5474-83. PubMed ID: 16027439
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I dose escalation and pharmacokinetic study of enzastaurin, an oral protein kinase C beta inhibitor, in patients with advanced cancer.
    Carducci MA; Musib L; Kies MS; Pili R; Truong M; Brahmer JR; Cole P; Sullivan R; Riddle J; Schmidt J; Enas N; Sinha V; Thornton DE; Herbst RS
    J Clin Oncol; 2006 Sep; 24(25):4092-9. PubMed ID: 16943527
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase I study of foretinib, a multi-targeted inhibitor of c-Met and vascular endothelial growth factor receptor 2.
    Eder JP; Shapiro GI; Appleman LJ; Zhu AX; Miles D; Keer H; Cancilla B; Chu F; Hitchcock-Bryan S; Sherman L; McCallum S; Heath EI; Boerner SA; LoRusso PM
    Clin Cancer Res; 2010 Jul; 16(13):3507-16. PubMed ID: 20472683
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I trial of pazopanib in patients with advanced cancer.
    Hurwitz HI; Dowlati A; Saini S; Savage S; Suttle AB; Gibson DM; Hodge JP; Merkle EM; Pandite L
    Clin Cancer Res; 2009 Jun; 15(12):4220-7. PubMed ID: 19509175
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase IA, open-label, dose-escalating study of PTK787/ZK 222584 administered orally on a continuous dosing schedule in patients with advanced cancer.
    Drevs J; Medinger M; Mross K; Fuxius S; Hennig J; Buechert M; Thomas A; Unger C; Chen BL; Lebwohl D; Laurent D
    Anticancer Res; 2010 Jun; 30(6):2335-9. PubMed ID: 20651389
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from two phase I studies.
    Morgan B; Thomas AL; Drevs J; Hennig J; Buchert M; Jivan A; Horsfield MA; Mross K; Ball HA; Lee L; Mietlowski W; Fuxuis S; Unger C; O'Byrne K; Henry A; Cherryman GR; Laurent D; Dugan M; Marmé D; Steward WP
    J Clin Oncol; 2003 Nov; 21(21):3955-64. PubMed ID: 14517187
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and efficacy of patupilone in patients with advanced ovarian, primary fallopian, or primary peritoneal cancer: a phase I, open-label, dose-escalation study.
    Ten Bokkel Huinink WW; Sufliarsky J; Smit WM; Spanik S; Wagnerova M; Hirte HW; Kaye S; Johri AR; Oza AM
    J Clin Oncol; 2009 Jul; 27(19):3097-103. PubMed ID: 19451434
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I dose-escalation study of oral vinflunine administered once daily for 6 weeks every 8 weeks in patients with advanced/metastatic solid tumours.
    Delord JP; Tourani JM; Lefresne F; Pétain A; Pouget JC; Ravaud A
    Cancer Chemother Pharmacol; 2013 Mar; 71(3):647-56. PubMed ID: 23299791
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety, pharmacokinetics, and efficacy of AMG 706, an oral multikinase inhibitor, in patients with advanced solid tumors.
    Rosen LS; Kurzrock R; Mulay M; Van Vugt A; Purdom M; Ng C; Silverman J; Koutsoukos A; Sun YN; Bass MB; Xu RY; Polverino A; Wiezorek JS; Chang DD; Benjamin R; Herbst RS
    J Clin Oncol; 2007 Jun; 25(17):2369-76. PubMed ID: 17557949
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase I study with neratinib (HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumors.
    Wong KK; Fracasso PM; Bukowski RM; Lynch TJ; Munster PN; Shapiro GI; Jänne PA; Eder JP; Naughton MJ; Ellis MJ; Jones SF; Mekhail T; Zacharchuk C; Vermette J; Abbas R; Quinn S; Powell C; Burris HA
    Clin Cancer Res; 2009 Apr; 15(7):2552-8. PubMed ID: 19318484
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I and pharmacokinetic study of halofuginone, an oral quinazolinone derivative in patients with advanced solid tumours.
    de Jonge MJ; Dumez H; Verweij J; Yarkoni S; Snyder D; Lacombe D; Marréaud S; Yamaguchi T; Punt CJ; van Oosterom A;
    Eur J Cancer; 2006 Aug; 42(12):1768-74. PubMed ID: 16815702
    [TBL] [Abstract][Full Text] [Related]  

  • 19. First study of the safety, tolerability, and pharmacokinetics of CP-724,714 in patients with advanced malignant solid HER2-expressing tumors.
    Munster PN; Britten CD; Mita M; Gelmon K; Minton SE; Moulder S; Slamon DJ; Guo F; Letrent SP; Denis L; Tolcher AW
    Clin Cancer Res; 2007 Feb; 13(4):1238-45. PubMed ID: 17317835
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase 1 open-label, accelerated dose-escalation study of the hypoxia-activated prodrug AQ4N in patients with advanced malignancies.
    Papadopoulos KP; Goel S; Beeram M; Wong A; Desai K; Haigentz M; Milián ML; Mani S; Tolcher A; Lalani AS; Sarantopoulos J
    Clin Cancer Res; 2008 Nov; 14(21):7110-5. PubMed ID: 18981010
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.